Navigation Links
InterMune to Release Third Quarter 2008 Financial Results on November 6
Date:10/28/2008

BRISBANE, Calif., Oct. 28 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) announced today that it will release third quarter 2008 financial results on Thursday, November 6, 2008 at 4:00 p.m. Eastern time. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

To access the live teleconference, dial 888-799-0528 (U.S.) or 706-634-0154 (international), conference ID# 71184785. To access the webcast, please log on to the company's website at http://www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 71184785.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
2. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
3. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
4. InterMune to Present at Canaccord Adams Conference
5. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
6. InterMune to Present at BMO Healthcare Conference
7. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
8. InterMune to Present at Jefferies Healthcare Conference
9. InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences
10. InterMune to Present at Citigroup Healthcare Conference
11. InterMune to Present at Bank of America Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... According to a new market research report "Oligonucleotide Synthesis Market ... (Research, PCR, Gene, DNA, NGS, Diagnostic, RNAI), End user (Academic, Pharmaceutical, ... is expected to reach USD 2.20 Billion by 2021 from USD ... forecast period. Continue Reading ... ...
(Date:12/8/2016)... ... December 08, 2016 , ... From wearable devices ... taking over sports. On Thursday, December 15th a panel of entrepreneurs, innovators and ... playing field at a Smart Talk session. Smart Talk will run from 8:30 ...
(Date:12/8/2016)... BELLINGHAM, Washington, USA, and CARDIFF, UK (PRWEB) , ... ... ... neural circuits with very high precision light to control cells — optogenetics — ... brain. In the current state of the art, spatially patterned light projected via ...
(Date:12/8/2016)... ... 2016 , ... KBioBox llc announced today the launch of ... a sophisticated “3 click” gene dditing off target analysis program and a “3 ... https://www.kbiobox.com/ and powered by the company’s proprietary BioEngine. Scientists, pharmaceutical researchers ...
Breaking Biology Technology:
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. ... has priced an offering of €500.0 million principal amount of ... principal amount of its 2.425% senior unsecured notes due 2026. ... to occur on December 13, 2016, subject to the satisfaction of ... annual basis. The Company intends ...
(Date:12/6/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring, and the Prison Entrepreneurship ... year funding commitment by Securus to PEP and ... reentry support to more inmates and their families. ... Prison Entrepreneurship Program (PEP) is an independent 501(c)(3) ...
(Date:12/2/2016)... 2016 The report "Biometric Vehicle ... Technology (Iris Recognition System), Vehicle Type (Passenger Car, ... to 2021", published by MarketsandMarkets, the market is ... and is projected to grow to USD 854.8 ...      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
Breaking Biology News(10 mins):